Literature DB >> 19597121

Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injection for wet age-related macular degeneration.

Paul Yih Seng Chua1, Izabela Mitrut, Ana-Marie Armbrecht, Archana Vani, Tariq Aslam, Baljean Dhillon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19597121     DOI： 10.1001/archophthalmol.2009.139

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  6 in total

1.  Exploring factors predicting changes in patients' expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration.

Authors:  S Sii; P Aspinall; S Borooah; B Dhillon
Journal:  Eye (Lond)       Date:  2017-12-08       Impact factor: 3.775

Review 2.  MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications.

Authors:  Ellis Meng; Tuan Hoang
Journal:  Adv Drug Deliv Rev       Date:  2012-08-19       Impact factor: 15.470

3.  Evaluation of patients' experiences at different stages of the intravitreal injection procedure - what can be improved?

Authors:  Rajen Tailor; Rebecca Beasley; Yit Yang; Niro Narendran
Journal:  Clin Ophthalmol       Date:  2011-10-14

Review 4.  Psychological impact of anti-VEGF treatments for wet macular degeneration-a review.

Authors:  Hugo Senra; Zaria Ali; Konstantinos Balaskas; Tariq Aslam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-04       Impact factor: 3.117

5.  Real-life patient journey in neovascular age-related macular degeneration: a narrative medicine analysis in the Italian setting.

Authors:  Edoardo Midena; Monica Varano; Elisabetta Pilotto; Giovanni Staurenghi; Monica Camparini; Alfredo Pece; Maurizio Battaglia Parodi; Maria Vadalà; Simone Donati; Luisa Frizziero; Alessandra Fiorencis; Maria Giulia Marini; Luigi Reale
Journal:  Eye (Lond)       Date:  2021-03-05       Impact factor: 3.775

6.  Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration.

Authors:  Youxin Chen; Fei Han
Journal:  Ther Clin Risk Manag       Date:  2012-07-11       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.